1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Lundbeck’s CNS Investments Are Delivering Returns

 
• By Jessica Merrill

The Danish company’s top line grew by 14% in 2024, driven by strong growth of brands like Rexulti, Brintellix and Vyepti, with continued growth expected.

(Shutterstock)
Key Takeaways

Lundbeck reported 14% revenue growth in 2024 on the strength of four drugs for CNS disorders.

Rexulti, in particular, is expected to be a continued growth-driver, driven by sales in agitation associated with Alzheimer’s and potentially expansion into PTSD.

Two pivotal trials are enrolling now for bexicaserin, the 5HT2C agonist Lundbeck acquired last year with Longboard Pharmaceuticals.

H. Lundbeck is squarely focused on central nervous system disorders, arguably one of the most challenging areas of drug development,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By Joseph Haas

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

More from Strategy

Battle For Obesity Market Shifts Gears in India: Will Wegovy Trump Mounjaro?

 
• By Anju Ghangurde

Novo Nordisk debuts Wegovy in India, gears for pole position in obesity. The Danish group’s leadership doesn’t appear too perturbed about the head start for Lilly’s Mounjaro or the imminent arrival of generic semaglutide next year.

Amgen’s MariTide Data Not The Hit Investors Sought

 
• By Joseph Haas

MariTide demonstrated solid 52-week weight loss in a Phase II update, but high rates of vomiting. Amgen is adjusting dosing in Phase III to seek a better tolerability profile.

Positive Fabry Data Should Smooth Way For Sangamo’s Partnering Efforts

 
• By Alaric DeArment

The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.